Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224971 · ClinicalTrials.gov registry record · Phase 2
Impact of Circadian Rhythm on Immunotherapy
A Phase 2 study of Advanced/Metastatic NSCLC, sponsored by Liza Villaruz, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT07224971 is a Phase 2 study of Advanced/Metastatic NSCLC that is actively recruiting participants, run by Liza Villaruz, MD. The registered enrollment target is 350 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07224971, a Phase 2 study of Advanced/Metastatic NSCLC, is actively recruiting participants, sponsored by Liza Villaruz, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Patients with any type of advanced/metastatic malignancy are eligible to enroll in this study, as long as first-line anti-PD-1/PD-L1 immunotherapy is on label for their condition. Participants will then be randomized to either the early treatment group (administration must start and conclude by 11:00 AM +1 hour window) or the late treatment group (administration must start after 12:00 PM).
Conditions Studied
Interventions
- DRUG Immunotherapy - PD-1 Blocker
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2030-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224971
The ClinicalTrials.gov registry entry for NCT07224971 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liza Villaruz, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced/Metastatic NSCLC appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy - PD-1 Blocker is the first listed.
NCT07224971 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07224971 about?
NCT07224971 is a clinical study titled "Impact of Circadian Rhythm on Immunotherapy". This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Patients with any type of advanced/metastatic malignancy are eligible to enroll in this study, as long as first-line anti-PD-1/PD-L1 immunothera...
What is the current status of trial NCT07224971?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2025-12-02. Estimated completion is 2030-05-01.
What conditions does trial NCT07224971 study?
This clinical trial studies the following conditions: Advanced/Metastatic NSCLC.
What interventions are being tested in trial NCT07224971?
The interventions under investigation include: Immunotherapy - PD-1 Blocker (DRUG).
Who is sponsoring clinical trial NCT07224971?
This trial is sponsored by Liza Villaruz, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224971 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.